Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
Executive Stance & Strategic Philosophy As CEO, the guiding principle is simple: Patient safety and regulatory integrity are non-negotiable. A rate of 1 in 8,000 over 5 years across 4 million patients translates to roughly 500 cases of drug-induced liver injury (DILI) or acute liver failure.Read the full answer
Assuming this is a U.S.-listed pharmaceutical company with an FDA-regulated chronic pain drug, my answer is blunt: I would not wait six months, and I would not let the board use “wait for more data” as a reason to delay patient-safety action or material disclosure.Read the full answer